The powerhouse of the cell

Driving a new means of fighting disease

Overview of our Patent-Pending MOT™ Technology

While conducting cancer research in the U.S., the benefits of mitochondria transplantation were discovered and exclusively licensed to MitoSense, under the name Mitochondria Organelle Transplantation (MOT™). During the past two years, MOT™ has shown tremendous promise in early research and testing. This early evidence indicates MOT™ may alleviate some symptoms associated with neurodegenerative disorders such as ALS, Alzheimer’s, Parkinson’s, and others. Further research and testing are under way.

There is currently no other therapy available like MOT™ and the early indications point to much broader applications, that could benefit millions of Americans suffering from various neurodegenerative issues and diseases.

Watch the promise of Mitochondria Organelle Transplantation (MOT™) to fight neurodegenerative diseases.

Validating Science

Dr. Elliott and Xian Peng Jiang display how Mitochondria organelle transplantation (MOT™) can restore mitochondrial function to inhibit cancer cell growth and reverse chemo-resistance.

Dr. Elliott and X.P. Jiang present background research on MOT™ in vitro and in vivo cell culture and animal models and exhibit proof of concept on ALS patient.

X.P. Jiang, Dr. Baucom, and Dr. Elliott transplant mitochondria into cells in vitro and in mice, which rescues aerobic respiration of diseased cells with mitochondrial dysfunction, showing promise for human neurodegenerative diseases.

MitoSense's Baucom and Jiang have also conducted research on how MOT™ technology can be a potential therapeutic for mitochondria dysfunction in patients suffering from severe cases of COVID-19.

Menzies, Cookson, and Taylor et al have discussed in detail mitochondrial dysfunction in a cell culture model of Familial Amyotrophic Lateral Sclerosis (FALS).

NASA research has identified mitochondrial health as a crucial component to the future of space travel

Mayo Clinic research in 2012 discovered that mitochondrial dysfunction is present early in Alzheimer's disease before memory loss.

Recent Mayo Clinic research has targeted mitochondria as a means of treating Alzheimer's disease.

Additional Alzheimer's research has shown that boosting mitochondrial health in mice reduced the number of amyloid plaques, thus resulting in improved cognitive function.

Scientist at the University of Copenhagen discover that mitochondrial DNA damage triggers spread of Parkinson’s disease-like pathology.

A study by the Buck Institute makes the case for boosting mitochondrial health as a means of slowing down or even reversing the effects of Alzheimer's and other neurodegenerative diseases.

Path Forward

We are actively forming partnerships with various public and private institutions to expand our research and reach, so we can help improve as many lives as possible.

The powerhouse of the cell

Driving a new means of fighting disease

Overview of our Patent-Pending MOT™ Technology

Watch the promise of Mitochondria Organelle Transplantation (MOT™) to fight neurodegenerative diseases.

ALS

The ALS Association recognizes
how mitochondrial dysfunction
occurs in those with ALS

Stanford study suggests that defects in mitochondria may contribute to Parkinson’s Disease

Parkinson's

Alzheimer's

Could disposing of
damaged mitochondria treat Alzheimer’s disease?

Applications

Mitochondria-targeted
therapeutics may help treat neurodegenerative diseases

Other neurodegenerative disorders

Data presented to the World Mitochondria Society supports MOT™ technology for TBI

Traumatic Brain Injury

Research shows that spaceflight impairs mitochondrial function

Space Travel

Validating Science

Path Forward